Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs GLS 5700 (Primary)
- Indications Zika virus infection
- Focus Adverse reactions
- Sponsors GeneOne Life Science
- 13 Jun 2017 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
- 13 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.